Abstract | PURPOSE OF REVIEW: Despite concerns regarding efficacy and tolerability, vancomycin continues to be the standard treatment for skin and soft tissue infections (SSTIs) when β- lactam antimicrobials cannot be used. This review sought to establish the role of both old and new alternatives to vancomycin. Methods for achieving optimization of vancomycin therapy are also explored. RECENT FINDINGS: SUMMARY: When vancomycin is used for the treatment of SSTIs, maximizing the dose should be performed to improve efficacy. Cost is often the main limiting factor with regard to the newer agents, but their suitability for outpatient antimicrobial therapy may counteract this.
|
Authors | Deirdre J O'Brien, Ian M Gould |
Journal | Current opinion in infectious diseases
(Curr Opin Infect Dis)
Vol. 27
Issue 2
Pg. 146-54
(Apr 2014)
ISSN: 1473-6527 [Electronic] United States |
PMID | 24526063
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Vancomycin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Humans
- Microbial Sensitivity Tests
- Skin Diseases, Bacterial
(drug therapy)
- Soft Tissue Infections
(drug therapy)
- Vancomycin
(therapeutic use)
|